Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Pharmacoeconomics|October 30, 2017
A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity AnalysisShijie Ren, Jonathan Minton, Sophie Whyte, et al.
Pharmacoeconomics|April 12, 2013
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisalJonathan Tosh, Rachel Archer, Sarah Davis, et al.
Critical Care (London, England)|November 29, 2025
Cost-effectiveness of procalcitonin-guided antibiotic duration for hospitalized patients with sepsisMatt Stevenson, Jessica E Forsyth, Anower Hossain, et al.
Journal of Medical Economics|January 24, 2022
Mean lifetime survival estimates following solid organ transplantation in the US and UKChristopher N Graham, Crystal Watson, Arie Barlev, et al.
Pharmacoeconomics|August 3, 2016
Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRachid Rafia, Alison Scope, Sue Harnan, et al.
Health Technology Assessment (Winchester, England)|March 4, 2020
Interventions to reduce the risk of surgically transmitted Creutzfeldt-Jakob disease: a cost-effective modelling reviewMatt Stevenson, Lesley Uttley, Jeremy E Oakley, et al.
Pharmacoeconomics|March 5, 2018
Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalShijie Ren, Iñigo Bermejo, Emma Simpson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|January 16, 2026
Target Trial Emulation to Incorporate Real-World Data in the Estimation of the Clinical and Cost-Effectiveness of Biologic TreatmentJanharpreet Singh, Matt Stevenson, Kimme L Hyrich, et al.
Pharmacoeconomics|June 9, 2018
Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalIñigo Bermejo, Shijie Ren, Emma Simpson, et al.
Cost Effectiveness and Resource Allocation : C/E|October 12, 2020
Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in USPraveen Thokala, Matt Stevenson, Varun M Kumar, et al.
Pageof 7